Abbott Receives FDA Authorization For Dual Glucose-Ketone Sensor

Abbott (NYSE: ABT) received FDA authorization for its Libre Duo 10 Day, the first dual glucose-ketone sensing technology. The biowearable monitors both glucose and ketone levels, helping detect rising ketones that can lead to diabetic ketoacidosis (DKA). Abbott plans to launch the product in the U.S. later this year, with compatibility with leading automated insulin delivery systems. The company aims to integrate the technology with multiple AID systems by the end of 2026 and 2027.

Abbott Laboratories (NYSE:ABT) agreed to pay $670M to settle NEC-related claims involving its preterm infant formulas, though it denies liability. The settlement resolves 2,000 cases but leaves 12,700 potential claims unresolved. Abbott reaffirmed its 2026 sales growth guidance and raised adjusted EPS outlook to $5.45-$5.60 after Q2 results. The company faces ongoing litigation and reputational risks, but its diversified business may absorb the costs.

Abbott Laboratories (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG) reported strong quarterly results, with Abbott raising its annual profit outlook and Intuitive beating revenue and earnings expectations. Abbott's diversification across diagnostics, medical devices, and nutrition drove growth, while Intuitive's robotic surgery ecosystem and recurring revenue model supported its performance. Despite the positive results, Intuitive's shares declined due to slowing domestic procedure growth. Abbot

Abbott Laboratories agreed to pay $670 million to settle around 2,000 lawsuits, including the Gill case, which accused the company of distributing infant formulas linked to necrotizing enterocolitis (NEC) in preterm babies. Abbott denies liability, stating the settlements are a compromise of disputed claims. The company faces additional pending lawsuits and scrutiny over heavy metals in its products.

FSSAI issued 150 notices to food companies, including Nestle India, PepsiCo, and Coca-Cola India, for misleading ads, false claims, and labeling violations. The regulator also took action against e-commerce platforms and food service establishments, suspending five Domino's licenses and canceling one Amazon warehouse license.

Abbott Laboratories (ABT) agreed to pay $670 million to settle around 2,000 lawsuits related to its premature infant formulas, including a $495 million verdict. The company denies wrongdoing but aims to resolve broader litigation. Abbott faces additional lawsuits, with a Chicago federal judge overseeing over 825 cases. Analysts suggest this settlement may set a precedent for future cases.